NYXH · Nyxoah SA
$1.62
+0.04 (+2.53%)
At close · Aug 14
Market Cap
$162.12M
Shares
100.07M
Nyxoah SA Earnings Call Transcripts
Every quarterly earnings call for Nyxoah SA (NYXH) — the full transcript with speaker labels, the audio replay, AI call highlights and a management-tone score, plus the matching 8-K earnings release and the quarter's 10-Q or 10-K. Investor days and conferences appear here too.
Earnings call
FY26 · Q2
2026-08-05
Earnings conference call (announced in 6-K)
Confident tone
Reimbursement and CMS coding
International growth
Sales force expansion
Results not yet reported
Audio
Transcript
Slides
8-K10-Q
Capital Markets Day
Investor event
2026-07-08
Investor Day 2026
No reported result — non-financial event
Audio
Transcript
Slides
Earnings call
FY26 · Q1
2026-05-12
Earnings conference call (announced in 6-K)
Confident tone
Financial Performance / Margins
Market Research / Surgeon Adoption
Disciplined OpEx / Cash Runway Management
Results not yet reported
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q4
2026-03-19
Earnings conference call (announced in 6-K)
Confident tone
U.S. commercial launch momentum
Reimbursement and CMS coding
Gross margin and next-gen product roadmap
Results not yet reported
Audio
Transcript
Slides
8-K10-K
Earnings call
FY25 · Q3
2025-09-30
Nyxoah SA Q3 FY2025 Earnings Call
Confident tone
U.S. Commercial Launch of Genio
Reimbursement and Payer Coverage
Gross Margin Trajectory
Results not yet reported
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q2
2025-06-30
Nyxoah SA Q2 FY2025 Earnings Call
Confident tone
Label differentiation and CCC strategy
Reimbursement and VAC/pre-authorization process
FDA PMA approval and U.S. launch
Results not yet reported
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q1
2025-03-31
Nyxoah SA Q1 FY2025 Earnings Call
Confident tone
CCC (complete concentric collapse) labeling
FDA PMA approval and manufacturing validation
Reimbursement and CPT code
Results not yet reported
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q4
2024-12-31
Nyxoah SA Q4 FY2024 Earnings Call
Confident tone
Genio product differentiation and DREAM clinical data
Reimbursement and CPT coding
Deferred revenue accounting change
Results not yet reported
Audio
Transcript
Slides
8-K10-K
Earnings call
FY24 · Q2
2024-06-30
Nyxoah SA Q2 FY2024 Earnings Call
Confident tone
Genio product differentiation
European commercial performance
GLP-1 drugs and OSA market expansion
Results not yet reported
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q4
2023-12-31
Nyxoah SA Q4 FY2023 Earnings Call
Results not yet reported
Audio
Transcript
Slides
8-K10-K
Earnings call
FY23 · Q3
2023-09-30
Nyxoah SA Q3 FY2023 Earnings Call
Results not yet reported
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q2
2023-06-30
Nyxoah SA Q2 FY2023 Earnings Call
Results not yet reported
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q1
2023-03-31
Nyxoah SA Q1 FY2023 Earnings Call
Results not yet reported
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q4
2022-12-31
Nyxoah SA Q4 FY2022 Earnings Call
Results not yet reported
Audio
Transcript
Slides
8-K10-K
Earnings call
FY22 · Q3
2022-09-30
Nyxoah SA Q3 FY2022 Earnings Call
Results not yet reported
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q2
2022-06-30
Nyxoah SA Q2 FY2022 Earnings Call
Results not yet reported
Audio
Transcript
Slides
8-K10-Q
Showing 1–16 of 16 earnings calls
Key facts
CIK
1857190
CUSIP
B6S7WD106
13F (30d)
45 filings
45 filers
Visit website
Investor relations